Clinical Trial Update: Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC) [NA]

View source ↗

Summary

A prospective, open-label study of Seraph 100 for long COVID has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid

Drugs mentioned

• Seraph 100

Snippet

Sponsor: ExThera Medical Corporation | Conditions: Long COVID | NA | Status: WITHDRAWN